Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Neurochondrin Drives Colorectal Cancer Progression by Modulating the PODXL–Ezrin Axis and Mitochondrial Function

ABSTRACT: Neurochondrin (NCDN) has been recently identified as overexpressed in liver metastatic colorectal cancer (CRC) cells compared to poorly metastatic isogenic counterparts. While its cellular function and role in cancer and CRC remain unknown, patient survival data indicate that elevated NCDN levels are associated with poor patients’ prognosis. After validating these observations in an independent patient cohort, we sought to investigate the role of NCDN in CRC progression using an isogenic CRC cell model comprising poorly metastatic KM12C cells and liver-metastatic KM12SM cells. Stable silencing of NCDN expression in both cell lines resulted in a marked reduction in their tumorigenic and metastatic properties in vitro. Furthermore, in vivo assays using nude mice demonstrated that NCDN is essential for tumor initiation, growth, and liver metastasis of CRC cells. Proteomic profiling of NCDN-silenced cells uncovered a set of dysregulated proteins associated with cell adhesion, invasion, cell death and differentiation, and mitochondrial function, showing that the NCDN-PODXL-Ezrin axis constitutes a critical mediator of CRC liver metastasis. Our findings position NCDN and their associated dysregulated proteins as drivers of metastatic progression in CRC and promising targets for further investigation.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Colon Cancer

SUBMITTER: Ana Montero Calle

LAB HEAD: Rodrigo Barderas

PROVIDER: PXD066531 | Pride | 2026-05-03

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	IP_NCDN_mAb.raw	Raw
	IP_NCDN_neg.raw	Raw
	mqpar.xml	Xml
	peptides.txt	Txt
	proteinGroups.txt	Txt

Items per page:

1 - 5 of 5

Similar Datasets

Functional proteomics characterization of the role of SPRYD7 in colorectal cancer progression and metastasis

Project description:SPRY domain-containing protein 7 (SPRYD7) is a barely known protein identified by spatial proteomics as upregulated in highly-metastatic to liver KM12SM colorectal cancer (CRC) cells in comparison to its isogenic poorly-metastatic KM12C CRC cells. Here, we aimed at analyzing SPRYD7 role in CRC by functional proteomics. By immunohistochemistry, the overexpression of SPRYD7 was observed to be associated to poor survival of CRC patients, and to an aggressive and metastatic phenotype. SPRYD7 stably overexpression was performed in KM12C and SW480 poorly-metastatic CRC cells, and in their isogenic highly-metastatic to liver KM12SM and to lymph nodes SW620 CRC cells, respectively. After confirming the upregulation of SPRYD7, in vitro and in vivo functional assays confirmed a key role of SPRYD7 in proliferation and migration of CRC cells. Furthermore, SPRYD7 was observed as an inductor of angiogenesis. In addition, the dysregulated SPRYD7-associated proteome and SPRYD7 interactors were elucidated by 10-plex TMT quantitative proteins, immunoproteomics, and bioinformatics. After WB validation, the biological pathways associated to the stably overexpression of SPRYD7 were visualized. In conclusion, it was demonstrated here that SPRYD7 is a novel protein associated to CRC progression and metastasis. Thus, SPRYD7 and its interactors might be of relevance to identify novel therapeutic targets for advanced CRC.

2024-01-26 | PXD042874 | Pride

Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis

Project description:Tropomodulin-2 (TMOD2) was previously identified as upregulated in the nuclear compartment of highly metastatic KM12SM colorectal cancer (CRC) cells. Here, we aimed to investigate its role using multiple CRC cell lines and patient-derived samples through functional proteomics, bioinformatics, and in vitro and in vivo analyses. TMOD2 expression was significantly elevated in highly metastatic CRC cells at both mRNA and protein levels, correlating TMOD2 high protein expression in CRC patients’ samples with advanced disease stages and poorer patient survival. To analyze TMOD2 role in CRC progression and metastasis, stable overexpression and transient depletion of TMOD2 was investigated in CRC isogenic cells with different metastatic properties. TMOD2 stable overexpression enhanced tumorigenic properties, including adhesion, anchorage-independent growth, and migration in CRC cells, whereas transient silencing of TMOD2 resulted in decreased adhesion and invasion capabilities, highlighting a role of TMOD2 in promoting metastasis. In vivo experiments confirmed the role of TMOD2 in enhancing tumor growth and liver metastasis, with TMOD2-overexpressing cells forming larger subcutaneous tumors and inducing poorly metastatic KM12C CRC cells to colonize the liver efficiently. DIA-LFQ proteomics and IP-LC-MS/MS analyses revealed significant dysregulation of proteins involved in cytoskeletal dynamics, secretion, and focal adhesion upon TMOD2 overexpression. Validation studies confirmed the specific involvement of key proteins, including STAG1 and MARCKS, in TMOD2-modulated pathways. Collectively, the results presented here suggest that TMOD2 plays a pivotal role in CRC progression by modulating cytoskeletal dynamics, enhancing cell adhesion, and promoting metastatic behavior, establishing TMOD2 as a potential therapeutic target in CRC.

2025-09-14 | PXD057950 | Pride

Downregulation of microRNA-132 is associated with liver metastasis of colorectal cancer by targeting Anoctamin 1.

Project description:In this study, we conducted a microarray-based analysis to identify differentially expressed miRNAs in CRC by comparing miRNA profiles among primary CRC tissues from patients with liver metastases, primary tissues without liver metastases, and liver metastatic lesions. microRNAs (miRNAs) have been shown to have a potential for cancer diagnosis lately. The main objective of this study is to identify a novel biomarker serum miRNA from the patients with colorectal cancer (CRC). Microarray analysis of miRNA expression was performed using paired pre- and post- operative serum from 10 CRC patients. Two miRNAs (let-7a, miR-199a-3p) decreased significantly in the post-operative serum when compared to pre-operative serum (P=0.015 and 0.029, respectively). Microarrays were performed for the testing cohort of primary CRC lesions (n=28) and liver metastatic lesions (n=8).

2016-02-14 | E-GEOD-72199 | biostudies-arrayexpress

Aryl hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis

Project description:Aryl hydrocarbon receptor-interacting protein (AIP), a putative positive intermediary in aryl hydrocarbon receptor-mediated signaling, is overexpressed in highly metastatic human KM12SM CRC cells, with high metastatic capacity to liver, and other highly metastatic CRC cells. Meta-analysis and immunohistochemistry were used to assess the relevance of this protein in CRC. Cellular functions and signaling mechanisms mediated by AIP were assessed by gain-of-function experiments and in vitro and in vivo experiments. A significant association of high AIP expression with poor CRC patients’ survival was observed. Gain-of-function and quantitative proteomics experiments demonstrated that AIP increased tumorigenic and metastatic properties of isogenic KM12C (poorly-metastatic) and KM12SM CRC cells. AIP overexpression dysregulated epithelial-to-mesenchymal (EMT) markers and induced several transcription factors and Cadherin-17 activation. The former induced the signaling activation of AKT, SRC, and JNK kinases to increase adhesion, migration and invasion of CRC cells. In vivo, AIP expressing KM12 cells induced tumor growth and liver metastasis. Furthermore, KM12C (poorly-metastatic) cells ectopically expressing AIP became metastatic to liver. Our data reveal new roles for AIP in regulating proteins associated with cancer and metastasis to induce tumorigenic and metastatic properties in colon cancer cells driving liver metastasis.

2023-05-10 | PXD031119 | Pride

Functional proteomics characterization of the role of SPRYD7 in colorectal cancer progression and metastasis

2024-01-26 | PXD042901 | Pride

Spatial Proteomic Analysis of Isogenic Metastatic Colorectal Cancer Cells Reveals Key Dysregulated Proteins Associated with Lymph Node, Liver and Lung Metastasis

Project description:Liver, lung and lymph nodes are the most common metatastic sites of colorectal cancer (CRC) cells. Here, we aimed to analyze by quantitative spatial proteomics the isogenic KM12 cell system (non-metastatic KM12C cells, liver metastatic KM12SM cells and liver and lung metastatic KM12L4a cells), and the isogenic non-metastatic SW480 and lymph nodes metastatic SW620 cells to study CRC metastasis. Cells were fractionated to study by proteomics five subcellular fractions corresponding to cytoplasm (CEB), membrane (MEB), nucleus (NEB), chromatin-bound proteins (NEB-CBP), and cytoskeletal proteins (PEB), and the secretome. Protein extracts were trypsin digested, labeled with TMT 11-plex and fractionated prior to proteomics analysis on a Q Exactive. We provide data on protein abundance and localization of 4031 proteins in their different subcellular fractions, depicting dysregulation of proteins in abundance and/or localization in the most common sites of CRC metastasis. Alterations in abundance and localization for selected proteins were validated via WB, IF, IHC and ELISA using CRC cells and patients’ tissue and plasma samples. These results supported the relevance of the proteomics results in a real-life scenario of CRC metastasis.

2022-02-22 | PXD030671 | Pride

Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis

Project description:Tropomodulin-2 (TMOD2) was previously identified as upregulated in the nuclear compartment of highly metastatic KM12SM colorectal cancer (CRC) cells. Here, we aimed to investigate its role using multiple CRC cell lines and patient-derived samples through functional proteomics, bioinformatics, and in vitro and in vivo analyses. TMOD2 expression was significantly elevated in highly metastatic CRC cells at both mRNA and protein levels, correlating TMOD2 high protein expression in CRC patients’ samples with advanced disease stages and poorer patient survival. To analyze TMOD2 role in CRC progression and metastasis, stable overexpression and transient depletion of TMOD2 was investigated in CRC isogenic cells with different metastatic properties. TMOD2 stable overexpression enhanced tumorigenic properties, including adhesion, anchorage-independent growth, and migration in CRC cells, whereas transient silencing of TMOD2 resulted in decreased adhesion and invasion capabilities, highlighting a role of TMOD2 in promoting metastasis. In vivo experiments confirmed the role of TMOD2 in enhancing tumor growth and liver metastasis, with TMOD2-overexpressing cells forming larger subcutaneous tumors and inducing poorly metastatic KM12C CRC cells to colonize the liver efficiently. DIA-LFQ proteomics and IP-LC-MS/MS analyses revealed significant dysregulation of proteins involved in cytoskeletal dynamics, secretion, and focal adhesion upon TMOD2 overexpression. Validation studies confirmed the specific involvement of key proteins, including STAG1 and MARCKS, in TMOD2-modulated pathways. Collectively, the result presented here suggest that TMOD2 plays a pivotal role in CRC progression by modulating cytoskeletal dynamics, enhancing cell adhesion, and promoting metastatic behavior, establishing TMOD2 as a potential therapeutic target in CRC.

2025-09-14 | PXD057708 | Pride

Neurochondrin Drives Colorectal Cancer Progression by Modulating the PODXL–Ezrin Axis and Mitochondrial Function

Project description:Neurochondrin (NCDN) has been recently identified as upregulated in metastatic to liver KM12SM colorectal cancer (CRC) cells in comparison to the poorly metastatic KM12C CRC cells. Furthermore, high levels of NCDN in patients correlate to a worse survival. In this work, using an independent patient cohort, we validated the worsened prognosis associated to NCDN’s elevated levels. Then, we sought to investigate the role of NCDN in CRC progression using the isogenic KM12 CRC cell model comprised of the aforementioned KM12C and KM12SM cells. Stable silencing of NCDN in both cell lines produced a reduction on the tumorigenic capacities of the cells in vitro as seen through different assays (proliferation, adhesion, colony formation…). In vivo, mice injected with the silenced cells had impaired tumor growth and metastasis compared to mice injected with the control cells. Proteomic profiling of NCDN-silenced cells uncovered a set of dysregulated proteins associated with NCDN such as PODXL, indicating that the NCDN-PODXL axis constitutes a critical mediator of CRC liver metastasis. Our findings position NCDN and their associated dysregulated proteins as drivers of metastatic progression in CRC.

2026-05-03 | PXD061002 | Pride

MicroRNA profiles discriminate among colon cancer metastasis

Project description:The aim of our study was to identify a microRNA signature for metastatic CRC that could predict and differentiate metastatic target organ localization. Normal and cancer tissues of three different groups of CRC patients were analyzed. RNA microarray and TaqMan Array analysis were performed on 66 italian patients with or without lymph nodes and/or liver recurrences. Data obtained with the two assays, were analyzed separately and then intersected to identify a primary CRC metastatic signature. Five differentially expressed microRNAs (hsa-miR-21, -103, -93, -31 and -566) were validated by qRT-PCR on a second group of 16 american metastatic patients. In situ hybridization was performed on the 16 american patients as well as on three distinct commercial tissues microarray (TMA), containing normal adjacent colon, the primary adenocarcinoma, normal and metastatic lymph nodes and liver. Hsa-microRNA-31,-21,-93, and-103 upregulation together with hsa-miR-566 downregulation defined the CRC metastatic signature, while in situ hybridization data identified a lymphonodal invasion profile. 33 patients had colon cancer with lymph nodes metastasis only (Any T, Any N, M0) and 15 were diagnosed with colon cancer, lymph nodes and liver metastases (Any T, Any N, M1). Separate tumor samples from the primary tumor, the metastatic lymph nodes and the liver metastasis were collected.

2014-04-01 | E-GEOD-56350 | biostudies-arrayexpress

Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer

Project description:In this study, we comprehensively charted the cellular landscape of colorectal cancer (CRC) and well-matched liver metastatic CRC using single-cell and spatial transcriptome RNA sequencing. We generated 41892 CD45- non-immune cells and 196473 CD45+ immune cells from 27 samples of 6 CRC patients, and found that CD8_CXCL13 and CD4_CXCL13 subsets increased significantly in liver metastatic samples that exhibited high proliferation ability and tumor-activating characterization, contributing to better prognosis of patients. Distinct fibroblast profiles were observed in primary and liver metastatic tumors. The F3+ fibroblasts enriched in primary tumors contributed to worse overall survival by expressing pro-tumor factors. However, the MCAM+ fibroblasts enriched in liver metastatic tumors might promote generation of CD8_CXCL13 cells through Notch signaling. In summary, we extensively analyzed the transcriptional differences of cell atlas between primary and liver metastatic tumors of CRC by single-cell and spatial transcriptome RNA sequencing, providing different dimensions of the development of liver metastasis in CRC

2023-02-22 | GSE225857 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data